Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Above 50 Day Moving Average – Time to Sell?

Seres Therapeutics, Inc. (NASDAQ:MCRB) shares crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $17.79 and traded as high as $17.90. Seres Therapeutics shares last traded at $16.94, with a volume of 44,852 shares traded.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d)” rating on shares of Seres Therapeutics in a report on Monday, December 8th. Canaccord Genuity Group raised their price objective on Seres Therapeutics from $14.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $14.33.

Seres Therapeutics Price Performance

The firm has a market capitalization of $153.31 million, a P/E ratio of -4.75 and a beta of 0.18. The company has a fifty day moving average of $17.79 and a 200 day moving average of $15.34.

Institutional Trading of Seres Therapeutics

Institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. increased its stake in shares of Seres Therapeutics by 40.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 21,679 shares in the last quarter. Invesco Ltd. increased its stake in Seres Therapeutics by 193.2% in the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 89,995 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Seres Therapeutics by 2,772.6% during the third quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock valued at $103,000 after purchasing an additional 5,157 shares during the period. XTX Topco Ltd bought a new position in shares of Seres Therapeutics during the 2nd quarter worth about $249,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Seres Therapeutics in the 3rd quarter valued at about $557,000. Institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.